BioLineRx (BLRX) Tops Q3 EPS by 8c

BioLineRx (NASDAQ: BLRX) reported Q3 EPS of $0.00, $0.08 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $430 thousand versus the consensus estimate of $4.62 million.

For earnings history and earnings-related data on BioLineRx (BLRX) click here.

You May Also Be Interested In

• Kalshi in early talks for IPO - The Information
• Alamos Gold Inc. (AGI:CN) (AGI) PT Lowered to Cdn$73 at BMO Capital
• Axis Capital Limited Downgrades Nippon Life India Asset Management Ltd (NAM:IN) to Add (2)